Key Details
Price
$1.40Annual ROE
289.46%Beta
0.61Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
ENV-105 targets CD105 proteins to restore sensitivity in cancer cells, enhancing the efficacy of existing therapies like ERLEADA and TAGRISSO. Kairos Pharma's ENV-105 aims to overcome resistance in CRPC and EGFR-mutant NSCLC, with key data releases expected in 2025. Financially, Kairos Pharma may need to raise funds by early 2025, leveraging positive interim data to boost stock prices.
LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / Kairos Pharma, (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.
LOS ANGELES, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit where he will be speaking with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group. The summit is being held virtually on October 15 – 17, 2024.
LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (“Kairos Pharma” or the “Company”) (NYSE American: KAPA), a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune suppression, announces that it has closed its initial public offering of 1,550,000 shares of common stock at an offering price of $4.00 per share. The gross proceeds to the Company from the offering were $6,200,000, before deducting underwriting discounts and commissions and other offering expenses. The Company's common stock began trading on the NYSE American LLC on September 16, 2024 under the symbol “KAPA.”
FAQ
- What is the ticker symbol for Kairos Pharma?
- Does Kairos Pharma pay dividends?
- What sector is Kairos Pharma in?
- What industry is Kairos Pharma in?
- What country is Kairos Pharma based in?
- When did Kairos Pharma go public?
- Is Kairos Pharma in the S&P 500?
- Is Kairos Pharma in the NASDAQ 100?
- Is Kairos Pharma in the Dow Jones?
- When was Kairos Pharma's last earnings report?
- When does Kairos Pharma report earnings?
- Should I buy Kairos Pharma stock now?